Tag Archives: GSK

Emerging Pharma Leaders: Jamey Millar, GSK

Storytelling, since time immemorial, has served an important role in conveying information, expectations, and obligations. Stories can function as orientation guides, uniting readers or listeners around a common set of assumptions. The best stories also contain an element of surprise, a reminder of the unexpected possibilities, and chance occurrences that bind our lives together. After […]
Posted in leadership | Also tagged , | Leave a comment

Pharma & Biotech Most Active Sector in UK M&As

The pharma, medical and biotech (PMB) sector, driven by the Novartis’s £8.6bn acquisition of GlaxoSmithKline’s oncology division, was the most active industry in UK M&A in H1 2014, with a 26.9% market share (£10.1bn), according to Mergermarket’s latest deal round-up. However M&A activity targeting the United Kingdom — standing at £37.5bn in H1 2014 — represented […]
Posted in Deals, Europe | Also tagged , , , | Leave a comment

GSK Submits Malaria Vaccine Candidate for EMA Approval

GSK announced that it has submitted a regulatory filing to the European Medicines Agency (EMA) for its malaria vaccine candidate, RTS,S. RTS,S is intended for use against the Plasmodium falciparum malaria parasite, which is most prevalent in sub-Saharan Africa (SSA). It is estimated that malaria accounts for approximately 90% of deaths in SSA, of which 77% occur […]
Posted in Europe, Global, Regulatory | Also tagged , , , | Leave a comment

FDA Warning to GSK Biologicals

FDA issued a warning letter to GlaxoSmithKline Biologicals (GSK), North America on June 12, 2014 for deviations from cCGMP requirements found during an inspection from Mar. 31 to Apr. 9, 2014 of its influenza vaccine manufacturing facility in Quebec. GSK is making progress in addressing FDA’s concerns and is working to meet supply commitments, the […]
Posted in FDA, Regulatory | Also tagged , | Leave a comment

GSK's Tykerb "Little More" to Offer

The future of GSK’s Tykerb (lapatinib) in the breast cancer market is unclear, after the combination of Tykerb and Herceptin in the large Phase III trial, ALTTO, showed no statistical superiority over Herceptin alone for improving disease-free survival, says research and consulting firm GlobalData.
Posted in Deals, healthcare, R&D | Also tagged , , , , | Leave a comment
  • Categories

  • Meta